ALX Oncology Holdings Inc

ALX Oncology Holdings Inc (ALXO) priced its initial public offering on Jul 17, 2020 at $19.00 per share, above its $15.00–$17.00 range, raising $161.5M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $669M. Jefferies was lead-left underwriter, joined by Credit Suisse, Piper Sandler and Cantor. Wilson Sonsini advised the company and Cooley advised the underwriters.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, which cancer cells use as a "don't eat me" signal. Its lead candidate, ALX148, has been dosed in over 150 subjects in combination with other anti-cancer agents.

Status

IPO

Ticker

ALXO

Exchange

Nasdaq Global Select

Priced

Jul 17, 2020

IPO price

$19.00

Price range

$15.00–$17.00

Raised

$161.5M

Market cap at IPO price

$669M

First filed

Jun 26, 2020

Underwriters

Jefferies, Credit Suisse, Piper Sandler and Cantor

Company counsel

Wilson Sonsini

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.